Key regions: Australia, Brazil, United Kingdom, Europe, Canada
The Other Vaccines market in G7 has been experiencing significant growth in recent years.
Customer preferences: The rising awareness about the importance of vaccination and the increasing prevalence of infectious diseases have been driving the demand for other vaccines in the G7 countries. Customers are becoming more conscious of their health and are willing to invest in preventive measures to avoid contracting diseases.
Trends in the market: The trend towards mandatory vaccinations for certain diseases has been a major driver of growth in the Other Vaccines market in G7. In addition, the rising demand for travel vaccines due to an increase in international travel has also contributed to the growth of the market. Moreover, the increasing number of clinical trials for vaccines and the development of new vaccines have been driving the growth of the market.
Local special circumstances: The demand for other vaccines varies across the G7 countries. For instance, Japan has a rapidly aging population and a high incidence of infectious diseases, which has led to a high demand for vaccines. On the other hand, the United States has a large population and a high incidence of infectious diseases, but the demand for vaccines is lower due to the lack of a national vaccination program.
Underlying macroeconomic factors: The G7 countries have a high level of healthcare expenditure and a well-developed healthcare infrastructure, which has supported the growth of the Other Vaccines market. In addition, the increasing prevalence of infectious diseases and the rising awareness about the importance of vaccination have been major drivers of growth in the market. The G7 countries also have a high level of research and development expenditure, which has led to the development of new vaccines and the growth of the market.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
